Salute e Benessere

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS…

PRESS RELEASE Amphista Therapeutics announces new data demonstratingin vivoefficacy and CNS activity of its mechanistically differentiated targeted protein degradersFirst demonstration of efficacy in disease-relevantin vivomodels for an orally delivered bifunctional non-cereblon /non-VHL-based protein degrader Deep degradation of target protein is achieved in a rapid, sustained, and highly selective manner Successful achievement of efficient CNS...
Nasdaq GlobeNewswire
24/01/2024

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial…

As a result of the efficacy evaluation of 42 patients participating in the phase 2 clinical trial, partial responses (PRs) were observed in 7 out of 42 patients. Furthermore, 3 out of 8 patients among 42 patients who were previously treated by immunotherapy experienced PRs (overall response rate, ORR 37.5%). As a result of the efficacy evaluation of 42 patients participating in the phase 2 clinical trial, partial responses (PRs) were observed in 7 out of 42 patients. Furthermore, 3 out of 8...
PR Newswire
24/01/2024

LG'S 'CARE FOR WHERE YOU LIVE: NEW HORIZON' CAMPAIGN EARNS TWO STARS FROM…

From concept to execution, LG's Care For Where You Live: New Horizon campaign placed sustainability at the forefront, integrating eco-conscious practices into many aspects of the filmmaking process. Tom Bartowicz, director of the campaign's inspirational and emotive film, sought to tell a sincere story with characters whose actions and behaviors organically express the value and virtue of eco-conscious living. From concept to execution, LG's Care For Where You Live: New Horizon campaign…
PR Newswire
24/01/2024

BioAro Inc to Host Inaugural Longevity Innovation Forum in Dubai, UAE

The Longevity Innovation Forum aims to bring together thought leaders, experts, and innovators in the field of healthy aging and longevity medicine to discuss the latest advancements, opportunities, and challenges in this rapidly evolving field. The roundtable will offer a unique platform for collaboration, knowledge sharing, and networking among professionals passionate about extending and improving human life. The Longevity Innovation Forum aims to bring together thought leaders, experts…
PR Newswire
24/01/2024

INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development…

The INTREPID Alliance was formed to bring together the collective industry expertise of its members across drug discovery, antiviral R&D, and medicine manufacturing to help prioritize the most promising assets in the drug development pipeline, support their advancement and catalyze new partnerships to fill in the gaps. This landscape analysis provides an initial look at the antiviral compounds currently under investigation that target 12 viral families selected by INTREPID with the greatest…
PR Newswire
24/01/2024

Implantable Drug Delivery Devices Global Market to Exhibit Growth at a…

Key Takeaways from the Implantable Drug Delivery Devices Market Report Key Takeaways from the Implantable Drug Delivery Devices Market Report To read more about the latest highlights related to the implantable drug delivery devices market, get a snapshot of the key highlights entailed in theGlobal Implantable Drug Delivery Devices Market Report Implantable Drug Delivery Devices Overview Implantable drug delivery devices represent a groundbreaking advancement in the field of...
PR Newswire
23/01/2024

CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period…

Key Takeaways from the CAR T-Cell Therapy Market Report Key Takeaways from the CAR T-Cell Therapy Market Report Discover which therapies are expected to grab the major CAR T-cell therapy market share @CAR T-Cell Therapy Market Report CAR T-Cell Therapy Overview CAR T-cells are formed by merging a chosen single-chain variable fragment from a particular monoclonal antibody with one or more intracellular signaling domains of T-cell receptors. Essentially, a CAR integrates...
PR Newswire
23/01/2024

The Global IV and Oral Iron Drugs Market Sees Explosive Growth, the Market to…

IV and Oral Iron Drugs Market Report Scope IV and Oral Iron Drugs Market Report Scope TheNorth Americais the largest market for the global IV and oral iron drugs market. The growing prevalence of Iron Deficiency Anemia is fueling the market's demand for intravenous (IV) and oral iron drugs. This condition is widespread among specific populations such as pregnant women, women of reproductive age, and individuals with chronic diseases. Increased awareness about iron deficiency anemia...
PR Newswire
23/01/2024

Caster Wheels Market to Worth $12 Billion by 2029, Comfort Casters Redefines…

Browse in-depth TOC on "Caster Wheels Market" Browse in-depth TOC on "Caster Wheels Market" 300 – Pages 124 - Tables 107 - Figures Caster Wheels Market Report Scope Caster manufacturers are consistently innovating to meet the diverse requirements of industries, such as manufacturing, logistics, healthcare, and hospitality, leading to a rising demand for customized caster designs. Companies like Comfort Casters are addressing the specific needs of...
PR Newswire
23/01/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of December 31, 2023(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (January 23, 2024 - 6:00 pm)– As of December 31, 2023, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses,...
Nasdaq GlobeNewswire
23/01/2024

Digital Therapeutics (DTx) Market Worth $21.9 Billion | MarketsandMarkets™

Browse in-depth TOC on "Digital Therapeutics (DTx) Market" Browse in-depth TOC on "Digital Therapeutics (DTx) Market" 290 - Tables 37 - Figures 309 - Pages Digital Therapeutics (DTx) Market Scope: The largest segment in the digital therapeutics market was acquired by treatment/care-related applications. The digital therapeutics market's application segment is divided into preventive and treatment/care-related applications. In 2022 the treatment/care-related...
PR Newswire
23/01/2024

Neuromod Devices Announces Finance Leadership Reorganisation

Neuromod was granted FDA approval for its first-of-a-kind tinnitus treatment device, Lenire, in 2023, which saw the technology company successfully launch in the United States of America resulting in exponential commercial growth. Neuromod was granted FDA approval for its first-of-a-kind tinnitus treatment device, Lenire, in 2023, which saw the technology company successfully launch inthe United States of Americaresulting in exponential commercial growth. The commercial growth combined...
PR Newswire
23/01/2024

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to…

Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control. Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis. Existing treatment options solely focus on managing symptoms and providing supportive care. Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control. Currently, there is no cure for these diseases…
PR Newswire
23/01/2024

Oncodesign Services, a Leading European CRO In Preclinical Drug Discovery…

This acquisition allows ODS to strengthen and extend its expertise and capabilities in the field of small molecule discovery to a fully integrated offering to support its customers' innovative programs from target validation to candidate selection. This acquisition allows ODS to strengthen and extend its expertise and capabilities in the field of small molecule discovery to a fully integrated offering to support its customers' innovative programs from target validation to candidate selection...
PR Newswire
23/01/2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

Company Announcement Net sales of DARZALEX ®in 2023 totaled USD 9,744 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ®(daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEXFASPRO®in the U.S.), as reported by...
Nasdaq GlobeNewswire
23/01/2024

Patient, Research and Industry Leaders Propose Biological Definition and First…

This landmark step forward was made possible by the breakthrough discovery of a test — validated in April 2023 by The Michael J. Fox Foundation's Parkinson's Progression Markers Initiative — capable of detecting the earliest believed pathology of PD even prior to the onset of any visible symptoms. The test, known as the alpha-synuclein seed amplification assay (αSyn-SAA), detects dysfunctional alpha-synuclein protein, one of the two biological hallmarks of PD alongside dopaminergic transport…
PR Newswire
23/01/2024

CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of…

First-of-its-kind, antibody-based, bivalent and bispecific MAGE-A4 T-cell engager CDR-Life Inc.today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development as a precision immunotherapy for solid tumors. First of its kind, CDR404 is an antibody-based, bivalent and bispecific MAGE-A4 T-cell engager (TCE) based on the company's unique M-gager ®technology for targeting...
Nasdaq GlobeNewswire
23/01/2024

FDA Grants Breakthrough Device Designation to Amadix´s preventive screening…

FDA's Breakthrough Devices Program is intended to provide patients and health care providers with timely access to novel medical devices by expeditingthe assessment and premarket approval process. The Breakthrough Devices Program reflects the FDA´s commitment to device innovation leading to more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases. FDA'sBreakthrough Devices Program is intended to provide patients and health care providers with...
PR Newswire
23/01/2024

Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin…

Vesper is currently expediting the development of VES001 for FTD(GRN) through ongoing Phase I studies that will include a Phase Ib Proof-of Concept in GRN mutation carriers in advance of potentially registrational Phase II/III trials, and for Phase I readiness of VES002, a treatment focused on a second central nervous system indication. Vesper is currently expediting the development of VES001 for FTD(GRN) through ongoing Phase I studies that will include a Phase Ib Proof-of Concept in GRN...
PR Newswire
23/01/2024

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing…

Solvias and Vertex Pharmaceuticals have worked together for several years to develop and validate test methods that are critical for the final release of patients' own edited cells, so that they can be delivered back to patients. The companies' collaboration included establishing the testing methods that will be scaled for commercializing CASGEVY. Solvias also has invested significantly in preparing one of its global facilities to support the commercial release work for this transformative…
PR Newswire
23/01/2024

Apollo Cancer Centres launches India's 1st AI-Precision Oncology Centre

Mr Dinesh Gundu Rao, State Minister for Health & Family Welfare, Karnataka, said, "As we inaugurate India's first AI-Precision Oncology Centre at Apollo Cancer Centres, Bengaluru, This pioneering initiative not only represents a monumental leap in medical technology but it also symbolises hope and progress for patients and caregivers. Apollo Hospitals' commitment to personalised oncology care through AI is a beacon of compassion and advancement, ensuring a brighter future for those…
PR Newswire
23/01/2024

Nomination Committee's proposal for Board of Directors of AB SKF

The Nomination Committee's additional proposals will be published in conjunction with the notice of the Annual General Meeting 2024. The Nomination Committee's additional proposals will be published in conjunction with the notice of the Annual General Meeting 2024. The Nomination Committee for the Annual General Meeting 2024 consists ofMarcus Wallenberg, FAM,Philip Ahlgren, Cevian Capital, Anders Algotsson, AFA Försäkring andAnders Jonsson, Skandia, together with the Chair of the...
PR Newswire
23/01/2024

Change in Orion Group Executive Management Board – René Lindell appointed Chief…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS23 JANUARY 2024 at 9.00 EET Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of OrionRené Lindell has been appointed Chief Financial Officer of Orion Group as of 1 May 2024. He will start already as of 1 April 2024 as Executive Advisor (until 30 April 2024) and member of the Group Executive Management Board and will report to President and CEO...
Nasdaq GlobeNewswire
23/01/2024

Ex dividend NOK 0.75 today

The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024.
Nasdaq GlobeNewswire
23/01/2024
Altri  Comunicati